##gff-version 3
##sequence-region O60934 1 754
O60934	UniProtKB	Chain	1	754	.	.	.	ID=PRO_0000231043;Note=Nibrin	
O60934	UniProtKB	Domain	24	83	.	.	.	Note=FHA;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00086	
O60934	UniProtKB	Domain	105	181	.	.	.	Note=BRCT	
O60934	UniProtKB	Region	111	328	.	.	.	Note=Mediates interaction with SP100;Ontology_term=ECO:0000250;evidence=ECO:0000250	
O60934	UniProtKB	Region	221	402	.	.	.	Note=Interaction with MTOR%2C MAPKAP1 and RICTOR;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23762398;Dbxref=PMID:23762398	
O60934	UniProtKB	Motif	461	467	.	.	.	Note=Nuclear localization signal	
O60934	UniProtKB	Motif	736	743	.	.	.	Note=EEXXXDDL motif	
O60934	UniProtKB	Compositional bias	448	451	.	.	.	Note=Poly-Gln	
O60934	UniProtKB	Modified residue	278	278	.	.	.	Note=Phosphoserine%3B by ATM;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10839544;Dbxref=PMID:10839544	
O60934	UniProtKB	Modified residue	337	337	.	.	.	Note=Phosphothreonine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
O60934	UniProtKB	Modified residue	343	343	.	.	.	Note=Phosphoserine%3B by ATM;Ontology_term=ECO:0000244,ECO:0000269,ECO:0000269;evidence=ECO:0000244|PubMed:23186163,ECO:0000269|PubMed:10802669,ECO:0000269|PubMed:10839545;Dbxref=PMID:23186163,PMID:10802669,PMID:10839545	
O60934	UniProtKB	Modified residue	347	347	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
O60934	UniProtKB	Modified residue	397	397	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244,ECO:0000244,ECO:0000244,ECO:0000244,ECO:0000269;evidence=ECO:0000244|PubMed:17525332,ECO:0000244|PubMed:18669648,ECO:0000244|PubMed:20068231,ECO:0000244|PubMed:23186163,ECO:0000269|PubMed:10839545;Dbxref=PMID:17525332,PMID:18669648,PMID:20068231,PMID:23186163,PMID:10839545	
O60934	UniProtKB	Modified residue	402	402	.	.	.	Note=Phosphothreonine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:20068231;Dbxref=PMID:20068231	
O60934	UniProtKB	Modified residue	432	432	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244,ECO:0000244,ECO:0000244,ECO:0000244,ECO:0000244;evidence=ECO:0000244|PubMed:16964243,ECO:0000244|PubMed:18669648,ECO:0000244|PubMed:20068231,ECO:0000244|PubMed:23186163,ECO:0000244|PubMed:24275569;Dbxref=PMID:16964243,PMID:18669648,PMID:20068231,PMID:23186163,PMID:24275569	
O60934	UniProtKB	Modified residue	509	509	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
O60934	UniProtKB	Modified residue	518	518	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
O60934	UniProtKB	Modified residue	615	615	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10839545;Dbxref=PMID:10839545	
O60934	UniProtKB	Modified residue	673	673	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
O60934	UniProtKB	Cross-link	529	529	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2);Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:28112733;Dbxref=PMID:28112733	
O60934	UniProtKB	Cross-link	571	571	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2);Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:28112733;Dbxref=PMID:28112733	
O60934	UniProtKB	Cross-link	582	582	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2);Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:28112733;Dbxref=PMID:28112733	
O60934	UniProtKB	Natural variant	93	93	.	.	.	ID=VAR_025792;Note=In some childhood acute lymphoblastic leukemia patients%3B uncertain pathological significance%3B rare variant. S->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11325820;Dbxref=dbSNP:rs12721593,PMID:11325820	
O60934	UniProtKB	Natural variant	95	95	.	.	.	ID=VAR_025793;Note=In some childhood acute lymphoblastic leukemia patients%3B uncertain pathological significance%3B rare variant. D->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11325820;Dbxref=dbSNP:rs61753720,PMID:11325820	
O60934	UniProtKB	Natural variant	105	105	.	.	.	ID=VAR_025794;Note=K->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.7;Dbxref=dbSNP:rs13312858	
O60934	UniProtKB	Natural variant	142	142	.	.	.	ID=VAR_051226;Note=N->S;Dbxref=dbSNP:rs769414	
O60934	UniProtKB	Natural variant	150	150	.	.	.	ID=VAR_025795;Note=In BC. L->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:14684699;Dbxref=dbSNP:rs773119929,PMID:14684699	
O60934	UniProtKB	Natural variant	171	171	.	.	.	ID=VAR_025796;Note=In some childhood acute lymphoblastic leukemia patients%3B uncertain pathological significance%3B rare variant%3B associated with aplastic anemia at homozygosity. I->V;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11325820,ECO:0000269|PubMed:15338273;Dbxref=dbSNP:rs61754966,PMID:11325820,PMID:15338273	
O60934	UniProtKB	Natural variant	185	185	.	.	.	ID=VAR_025797;Note=E->Q;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:14684699,ECO:0000269|PubMed:14688016,ECO:0000269|PubMed:14702039,ECO:0000269|PubMed:9590180,ECO:0000269|PubMed:9590181,ECO:0000269|Ref.7;Dbxref=dbSNP:rs1805794,PMID:14684699,PMID:14688016,PMID:14702039,PMID:9590180,PMID:9590181	
O60934	UniProtKB	Natural variant	210	210	.	.	.	ID=VAR_025798;Note=V->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11325820;Dbxref=dbSNP:rs61754796,PMID:11325820	
O60934	UniProtKB	Natural variant	215	215	.	.	.	ID=VAR_025799;Note=R->W;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11325820;Dbxref=dbSNP:rs34767364,PMID:11325820	
O60934	UniProtKB	Natural variant	216	216	.	.	.	ID=VAR_025800;Note=Q->K;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.7;Dbxref=dbSNP:rs769416	
O60934	UniProtKB	Natural variant	266	266	.	.	.	ID=VAR_025801;Note=P->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.7;Dbxref=dbSNP:rs769420	
O60934	UniProtKB	Natural variant	408	408	.	.	.	ID=VAR_051227;Note=K->E;Dbxref=dbSNP:rs34120922	
O60934	UniProtKB	Natural variant	497	497	.	.	.	ID=VAR_025802;Note=T->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.7;Dbxref=dbSNP:rs3026268	
O60934	UniProtKB	Natural variant	574	574	.	.	.	ID=VAR_025803;Note=L->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:14684699;Dbxref=dbSNP:rs142334798,PMID:14684699	
O60934	UniProtKB	Natural variant	679	679	.	.	.	ID=VAR_064738;Note=Found in a renal cell carcinoma sample%3B somatic mutation. Y->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21248752;Dbxref=PMID:21248752	
O60934	UniProtKB	Mutagenesis	28	28	.	.	.	Note=Disrupts nuclear foci formation and block phosphorylation in response to ionizing radiation. R->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10802669;Dbxref=PMID:10802669	
O60934	UniProtKB	Mutagenesis	45	45	.	.	.	Note=Disrupts nuclear foci formation and block phosphorylation in response to ionizing radiation. H->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10802669;Dbxref=PMID:10802669	
O60934	UniProtKB	Mutagenesis	136	137	.	.	.	Note=Disrupts nuclear foci formation and block phosphorylation in response to ionizing radiation. GG->EE;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10802669;Dbxref=PMID:10802669	
O60934	UniProtKB	Mutagenesis	176	176	.	.	.	Note=Disrupts nuclear foci formation and block phosphorylation in response to ionizing radiation. Y->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10802669;Dbxref=PMID:10802669	
O60934	UniProtKB	Mutagenesis	343	343	.	.	.	Note=Abrogates ATM-dependent phosphorylation. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10839545;Dbxref=PMID:10839545	
O60934	UniProtKB	Mutagenesis	397	397	.	.	.	Note=Abrogates ATM-dependent phosphorylation. No loss of interaction with KPNA2. S->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10839545,ECO:0000269|PubMed:16188882;Dbxref=PMID:10839545,PMID:16188882	
O60934	UniProtKB	Mutagenesis	465	466	.	.	.	Note=Blocks the association with KPNA2%2C and reduces nuclear foci formation in response to ionizing radiation. KR->AA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16188882;Dbxref=PMID:16188882	
O60934	UniProtKB	Mutagenesis	583	583	.	.	.	Note=No loss of interaction with KPNA2. Q->K;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16188882;Dbxref=PMID:16188882	
O60934	UniProtKB	Mutagenesis	615	615	.	.	.	Note=Abrogates ATM-dependent phosphorylation. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10839545;Dbxref=PMID:10839545	
O60934	UniProtKB	Mutagenesis	736	737	.	.	.	Note=Decreases ATM binding. EE->AA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15758953;Dbxref=PMID:15758953	
O60934	UniProtKB	Mutagenesis	741	742	.	.	.	Note=Decreases ATM binding. DD->AA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15758953;Dbxref=PMID:15758953	
O60934	UniProtKB	Mutagenesis	745	746	.	.	.	Note=Decreases ATM binding. RY->AA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15758953;Dbxref=PMID:15758953	
O60934	UniProtKB	Sequence conflict	247	247	.	.	.	Note=G->R;Ontology_term=ECO:0000305;evidence=ECO:0000305	
O60934	UniProtKB	Turn	426	429	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5WQD	
